People | February 09, 2022
Strand Therapeutics appoints Dr. Prashant Nambiar as Senior VP
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
The CAS SciFinder Discovery Platform expansion unlocks human-indexed insights from journals and patents in over 50 languages dating back to 1957 and 70 million biosequences curated by CAS scientists
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
The study will be published on the pre-print server, medRXiv, shortly
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
Subscribe To Our Newsletter & Stay Updated
